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For the first time in Asia, in July 2011, Korea introduced using 
chemical castration on sexual offenders. Under the current law, 
perpetrators of sexual crimes against minors aged less than 16 
yr are subject to chemical castration. There have been growing 
calls for tougher punishment against sexual offenders and 
stronger preventive measures in the aftermath of a series of vio-
lent crimes victimizing women and children. Recently, a Cabi-
net meeting approved a revised bill, under which Korea will ex-
pand chemical castration to include those convicted of sexual 
crimes against minors under age 19, and retroactively apply the 
laws governing sexual offender personal information disclo-
sure.
 Using hormonal drugs to reduce sexual violence recidivism 
is known as chemical castration. The first reported attempt of 
hormonal manipulation to reduce pathological sexual behavior 
occurred in 1944, when diethylstilbestrol was prescribed to low-
er testosterone levels (1). Medroxyprogesterone acetate and cy-
proterone acetate have been used throughout the United States, 
Canada, and some European countries to diminish sexual fan-
tasies and sexual impulses in sexual offenders (2). A more re-
cent and promising development in the treatment of paraphil-
ias is using luteinizing hormone releasing hormone (LHRH) 
agonists such as leuprolide acetate and goserelin. In 1996, Cali-
fornia became the first state in the United States to authorize 
the use of either chemical or surgical castration for certain sex-
ual offenders who were being released from prison into the 
community. This legislation was extremely controversial at 
the time (3); however, eight additional states have subsequent-
ly passed laws that provide some form of castration for sexual 
offenders under consideration for parole or probation. Cur-
rently, similar debates on the legislation and expansion of 
chemical castration have taken place in Korea. 
 Testosterone is the major hormone associated with libido 
and sexual function, and several studies have reported that vio-
lent sexual offenders have higher levels of androgens than do 
nonviolent comparison groups and androgen levels correlate 
positively with both prior violence and the severity of sexual ag-
gression (4-6). However, a clear cause-and-effect relationship 
between testosterone levels and sexual offending remains un-
certain (7). Nevertheless, various comprehensive theories of 
sexual offending have incorporated hormonal factors despite 
surprisingly little evidence (8), and both surgical and chemical 
castration undoubtedly reduce sexual interest, sexual perfor-
mance, and sexual reoffending (9). 
 Surgical castration reportedly produces definitive results, even 
in repeat pedophilic offenders, by reducing recidivism rates to 
2% to 5% compared with expected rates of 50%. Chemical cas-
tration using LHRH agonists reduces circulating testosterone to 
very low levels, and also results in very low levels of recidivism 
despite the strong psychological factors that contribute to sexual 
offending (10). Chemical castration has some advantages over 
surgical castration. First, although chemical castration is poten-
tially life-long for some offenders, it might allow sexual offend-
ers to have normal sexual activity in context with psychothera-
py. Second, some sexual offenders may voluntarily receive chem-
ical castration. Third, chemical castration may be a more realis-
tic restriction than electronic ankle bracelets or surgical castra-
tion. Fourth, unlike surgical castration, the effects of anti-libido 
medication are reversible after discontinuation. Finally, the gen-
eral public may feel relieved knowing that sexual offenders are 
undergoing chemical castration.
 Nevertheless, there has been an ongoing debate about chem-
ical castration for a variety of social and medical reasons. Social 
problems include that chemical castration may not guarantee 
human rights for involuntary cases performed without informed 
consent of the sexual offender, and thus may be regarded as only 
punishment and not treatment. Chemical castration has been 
executed without informed consent in Korea and in three states 
of the Unites States (2). Additionally, increasing the population 
of sexual offenders who undergo chemical castration will cre-
ate tremendous socioeconomic burdens. It costs 5 million won 
(USD 4,650) per person annually for medication and monitor-
ing when leuprolide acetate injections are administered every 
3 months in Korea. 
 Medical considerations are also important, and contemporary 
doctors should be knowledgeable of these issues. First, chemi-
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cal castration is no longer effective after it is discontinued; there-
fore, the spontaneity for receiving medication is prerequisite to 
overcoming this limitation. World Federation of Societies of Bi-
ological Psychiatry guidelines suggest that combined psycho-
therapy and pharmacological therapy is associated with better 
efﬁcacy compared with either treatment as monotherapy (10). 
Furthermore, as we have experienced in treating prostate can-
cer, chemical castration may have serious side effects. Drugs 
such as medroxyprogesterone acetate, cyproterone acetate, and 
LHRH agonists, when administered for chemical castration, can 
induce a significant decline not only in serum testosterone but 
also in estradiol. Estrogens play an important physiological role 
even in men because they have beneficial effects on skeletal 
growth and bone maturation, brain function, and cardiovascu-
lar biology. Therefore, chemical castration is associated with 
various side effects, including osteoporosis, cardiovascular dis-
ease, and impaired glucose and lipid metabolism (11). Depres-
sion, hot flashes, infertility, and anemia can also occur. Given 
that the minimal duration of treatment is 3 to 5 yr for severe para-
philia when a high risk of sexual violence exists (10), the side ef-
fects of chemical castration can increase in a time-dependent 
manner.  
 Sexual crimes are a significant public health problem, efforts 
to prevent recidivism and protect the community are worthy, 
and public safety can take precedence over criminal’s rights. 
Chemical castration reduces recidivism effectively when offered 
to sexual offenders within the context of simultaneous compre-
hensive psychotherapeutic treatment. However, chemical cas-
tration under the current laws is vaguely positioned between 
punishment and treatment due to lack of informed consent by 
the recipient, and so remains a problematic issue for medical 
ethics. Therefore, physicians are obligated to very closely moni-
tor any potential treatment complications in sexual offenders 
undergoing chemical castration.
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